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Monocarboxylate transporter 1 (MCT1) inhibition is
thought to block tumor growth through disruption
of lactate transport and glycolysis. Here, we show
MCT1 inhibition impairs proliferation of glycolytic
breast cancer cells co-expressing MCT1 and MCT4
via disruption of pyruvate rather than lactate export.
MCT1 expression is elevated in glycolytic breast tu-
mors, and highMCT1 expression predicts poor prog-
nosis in breast and lung cancer patients. AcuteMCT1
inhibition reduces pyruvate export but does not
consistently alter lactate transport or glycolytic flux
in breast cancer cells that co-express MCT1 and
MCT4. Despite the lack of glycolysis impairment,
MCT1 loss-of-function decreases breast cancer cell
proliferation and blocks growth of mammary fat
pad xenograft tumors. Our data suggest MCT1
expression is elevated in glycolytic cancers to pro-
mote pyruvate export that when inhibited, enhances
oxidative metabolism and reduces proliferation. This
study presents an alternative molecular conse-
quence of MCT1 inhibitors, further supporting their
use as anti-cancer therapeutics.1590 Cell Reports 14, 1590–1601, February 23, 2016 ª2016 The AuthINTRODUCTION
Given that glycolytic metabolism contributes to tumor growth in
many cancers, efforts have beenmade to block tumor glycolysis
by inhibiting the monocarboxylate transporters (MCTs) that
regulate cancer cell lactate export. The MCT family includes 14
members, but only MCT1-4 have been demonstrated to mediate
proton-linked bi-directional transport of monocarboxylates such
as lactate, pyruvate, and ketone bodies across the plasmamem-
brane (Halestrap and Meredith, 2004). Tumor lactate export is
thought to be primarily mediated by MCT1 and MCT4, since
these are the family members most commonly upregulated in
cancers (Halestrap and Meredith, 2004; Halestrap and Wilson,
2012). SLC16A1, the gene that encodes MCT1, was recently re-
ported to be a MYC transcriptional target essential for lactate
transport and glycolytic flux of certain cancer cell lines (Doherty
et al., 2014). MCT1 inhibition induces cell death in Burkitt lym-
phoma cells and MCF7 breast cancer cells through disruption
of lactate export, glycolysis, and glutathione synthesis (Doherty
et al., 2014). Consistently, small molecule inhibitors of MCT1
block activation of T cells reliant on increased glycolysis for pro-
liferation through abrogation of lactate export (Guile et al., 2006;
Murray et al., 2005). AZD3965 is aMCT1 inhibitor that is currently
undergoing phase I evaluation in the United Kingdom for patients
with solid tumors, prostate cancer, gastric cancer, and diffuse
large cell B lymphoma (Polanski et al., 2014). Multiple studies,ors
(legend on next page)
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including one using AZD3965, show that MCT4 expression can
portend resistance to MCT1 inhibition. Consistent with previous
studies, here, we show that MCT1 expression correlates with
breast cancer glycolytic phenotype and aggressiveness. How-
ever, we also find that MCT1 loss-of-function reduces pyruvate,
but not lactate export in glycolytic breast cancer cells that co-
express MCT1 and MCT4, which leads to enhanced oxidative
metabolism and decreased proliferation, thus presenting an
alternative mode of action of MCT1 inhibitors.
RESULTS
Unbiased Gene Expression Analysis Finds that MCT1
mRNA Levels Correlate with Glycolytic Metabolism in
Breast Cancer Cells
To identify specific transcriptional events that correlate with
glycolytic phenotype in breast cancer, we analyzed gene expres-
sion profiles from 11 patient breast tumors stratified by F-18 flu-
orodeoxyglucose (FDG) uptake and 31 breast cancer cell lines
that we stratified based on glycolytic versus oxidative phenotype
(nmol lactate produced/nmol oxygen consumed) (Figures S1A
and S1B) (Neve et al., 2006; Palaskas et al., 2011). As shown in
Figure 1A, tumors with high FDG uptake exhibit a distinct tran-
scriptional signature from those with low FDG uptake. Gene
Set Enrichment Analysis confirmed that MYC-regulated gene
sets are significantly enriched in the glycolytic breast tumors
and cell lines (Figure S1C; Table S1) (Palaskas et al., 2011). Addi-
tionally, Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways involved in nucleotide metabolism and glycolysis are
also enriched in the glycolytic tumors and cell lines (Figure 1A;
Table S2) (Kanehisa et al., 2014). Consistent with previous find-
ings (Palaskas et al., 2011), the glycolytic tumor and cell line gene
expression signature significantly correlates with the basal gene
expression signature in breast cancer (Chang et al., 2005) (Fig-
ures S1D and S1E). Mapping the glycolytic gene expression
signature to the KEGG glycolysis pathway demonstrates coordi-
nated upregulation of glycolytic genes including HK2, PFKP,
BPGM, ENO3, and LDHB (Figures 1B, S1F, and S1G). Together,
these data demonstrate that glycolytic tumors and cell lines
exhibit a gene expression signature consistent with the Warburg
effect.
Notably, the top-ranked transcript correlating with glycolytic
phenotype in breast tumors and cell lines is Solute CarrierFigure 1. Unbiased Gene Expression Analysis Finds that MCT1 Correla
(A) Breast tumors with high and low FDG uptake have distinct gene expression s
average correlation with tumor FDG maximum standardized uptake value (SUV
consumed) and arranged from left to right in order of increasing FDG uptake. Red
MCT1 is the top-ranked of 13,374 genes. The inset table lists metabolic pathway
pathway; Glyc/Gluc, glycolysis/gluconeogenesis).
(B) Highly glycolytic tumors and cell lines demonstrate coordinate upregulation o
red or green to denote high and low correlation coefficients with glycolytic phen
(C) Levels of MCT1, but not other MCT family members, are highly correlated wit
coefficient with FDG uptake in human breast tumors (left) and glycolytic phenoty
recognizing MCT1-4 family members.
(D) Scatter plots of MCT1 and MCT4 expression demonstrate that MCT1 but no
plotted versus FDG uptake for human breast tumors (left) and glycolytic phen
significance of the Pearson correlation coefficient.
See also Figure S1 and Tables S1 and S2.
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MCT1-4 mediate monocarboxylate transport in cells, we
analyzedmRNA expression patterns of the corresponding genes
in breast tumors and cell lines (Figures 1B and 1C). Only MCT1
mRNA expression yields consistently strong correlation coeffi-
cients with glycolytic phenotype in both breast tumors and cell
lines (Figures 1B–1D). In contrast, MCT4 mRNA expression is
less correlated with glycolytic phenotype (Figures 1B–1D). How-
ever, MCT1-4mRNA levels in cancer cellsmay not reflect protein
levels or transporter activity, especially sinceMCT4mRNA levels
have been shown to correlate poorly with protein levels inmuscle
(Bonen et al., 2000).
MCT1 Protein Levels Are Elevated in Malignant Breast
and Lung Cancer Lesions
To determine whether MCT1 protein expression is elevated in
primary cancers, we analyzed normal and malignant breast
and lung tissues by immunohistochemistry using high-density
tissue microarrays (TMAs). MCT1 protein expression is signifi-
cantly increased in malignant breast and lung tissues compared
to adjacent non-malignant tissues (Figures 2A–2C). Later stage
lung cancers (stages II–IV) have greater MCT1 expression than
those in early stages (stage I) (integrated intensity = 0.44 ±
0.08 in stages II–IV [n = 174] versus integrated intensity =
0.29 ± 0.03 in stage I [n = 216], p < 0.01). Additionally, high
MCT1 expression is associated with worse prognosis in breast
and lung cancer patients (Figures 2D and 2E). These findings
corroborate published results showing MCT1 elevation in
basal-like breast carcinoma (Pinheiro et al., 2010) and colorectal
carcinomas (Pinheiro et al., 2008) as well as studies showing as-
sociation of MCT1 expression with poor prognosis in epithelial
ovarian cancer (Chen et al., 2010) and gastric cancer (Pinheiro
et al., 2009). These results are inconsistent with a previous report
that did not find elevated MCT1 expression by immunohisto-
chemistry in lung adenocarcinomas (McCleland et al., 2013).
One potential explanation for this discrepancy is the use of
more lung adenocarcinoma patient samples in our study (715
versus 226). Additionally, while we found significantly elevated
MCT1 expression in lung adenocarcinomas compared to adja-
cent non-malignant tissue, we found an even greater increase
in MCT1 expression in squamous cell and large cell carcinoma
tissues. Furthermore, we found that serum lactate and pyruvate
concentrations are significantly elevated in stage IV versustes with Glycolytic Phenotype in Breast Cancer
ignatures. Transcript levels from 11 human breast cancers were ranked by the
max) and cell line glycolytic phenotype (nmol lactate produced/nmol oxygen
and green denote high and low average correlation coefficients, respectively.
s enriched in highly glycolytic tumors and cell lines (PPP, pentose phosphate
f glycolysis genes and MCT1. Genes within the glycolysis pathway are colored
otype, respectively.
h glycolytic phenotype in breast tumors and cell lines. The Pearson correlation
pe in human breast cancer cell lines (right) is depicted for microarray probes
t MCT4 is highly correlated with glycolytic phenotypes. Transcript levels are
otype for human breast cancer cell lines (right). p values are the two-tailed
ors
(legend on next page)
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stage I lung cancer patients (Figure 2F), consistent with MCT1
modulation of tumor cell lactate and pyruvate export in vivo.
However, no significant difference in lactate or pyruvate levels
was observed in serum from stage IV versus stage I breast can-
cer patients (data not shown).
MCT1 Inhibition Reduces Pyruvate, but Not Lactate
Export, and Enhances Oxidative Metabolism in
Glycolytic Breast Cancer Cells
Given that MCT1 levels are elevated in glycolytic and malignant
breast tumors, we hypothesized that MCT1 may contribute to
theWarburg effectmetabolic phenotype. To test this hypothesis,
we generated breast cancer cell lines with short hairpin RNA
(shRNA)-mediated stable knockdown of MCT1 (Figure S2A).
The cell lines used—HS578T, SUM149PT, and SUM159PT—
are among the most glycolytic in our panel of 31 breast cancer
cell lines (Figure S1B). Using a threshold-free comparison of
genome-wide expression patterns (Plaisier et al., 2010), we
found that MCT1 knockdown in SUM149PT cells abrogated
the similarity of these glycolytic cells to tumors with high FDG
uptake (Figure 3A). Additionally, MCT1 knockdown results in
altered expression of several nodes associated with highly
glycolytic phenotypes, including HK1, PFKM. BPGM, and
ENO1 (Figure S2B). Treatment of HS578T cells for 24 hr with
an MCT1 inhibitor (AZD3965) induced a gene expression signa-
ture that strongly resembles that of SUM149PT cells with stable
MCT1 knockdown (Figure S2C). Treatment of SUM149PT and
SUM159PT cells with theMCT1 inhibitor abrogated the similarity
to SUM149PT cells expressing scrambled shRNA. Additionally,
MCT1 inhibition decreased the similarity of these glycolytic cells
to tumors with high FDG uptake (Figure S2D). Gene set enrich-
ment analysis (GSEA) of MCT1 knockdown SUM149PT cells,
as well as MCT1 inhibitor (AZD3965)-treated SUM149PT cells,
showed enrichment in genes involved in oxidative phosphoryla-
tion, pyruvate metabolism, the TCA cycle, and, surprisingly,
glycolysis (Figures 3B and S2E). Enriched expression of oxida-
tive phosphorylation genes was also observed upon MCT1 inhi-
bition for 24 hr in additional breast cancer cell lines (Figure S2F).
Consistently, MCT1 inhibition results in increased oxygen con-Figure 2. Elevated MCT1 Levels Are Indicative of Tumor Malignancy a
(A) Immunohistochemistry of human normal breast and breast invasive ductal carc
in the malignant tissue. Images are shown at 1003 magnification.
(B) The mean integrated MCT1 expression as determined by immunohistochem
histopathologies. MCT1 expression is significantly increased in ductal carcinoma
nodemetastatic lesions (LNmets) (p = 0.004) compared to adjacent non-malignan
(BR). There is no significant difference between normal breast glandular epithe
n, number of tissue array spots analyzed.
(C) The mean integrated MCT1 expression as determined by immunohistochem
topathologies. MCT1 expression is significantly increased in adenocarcinoma (Ad
(p < 0.001) and large cell (p < 0.001) compared to adjacent non-malignant bronc
large cell tumors compared to adenocarcinomas and adeno-squamous tumors
analyzed.
(D) Higher MCT1 expression levels predict poorer survival in women with invasive
lowerMCT1 expression (<2.0 mean integrated intensity) depicted as a green line a
line. n, number of individuals in each category.
(E) Higher MCT1 expression levels predict poorer survival in individuals with NS
(%1.0 mean integrated intensity) depicted as a green line and higher MCT1 exp
individuals in each category.
(F) Serum lactate (left) and pyruvate (right) concentrations from stage I versus sta
1594 Cell Reports 14, 1590–1601, February 23, 2016 ª2016 The Authsumption rates in multiple breast cancer cell lines after 24 hr
treatment, but not after 0.5 or 4 hr AZD3965 treatment (Figures
3C and S3A–S3C). Notably, however, lactate export rates are
not consistently altered upon MCT1 inhibition (Figures 3D,
S3D, and S3E) or MCT1 knockdown (Figure S3F). Additionally,
glycolytic flux as determined by conversion of 1,2-13C-glucose
to 1,2-13C-lactate is also not consistently altered by MCT1 inhi-
bition in breast cancer cell lines (Figures 3E and S3G). These
data suggest that MCT1 inhibition leads to enhanced oxidative
metabolism in breast cancer cells through an alternative mecha-
nism than reduced lactate export and disrupted glycolysis.
Given that MCT1 has been shown to regulate lactate uptake in
cultured endothelial cells and certain cancer cell lines (Sonveaux
et al., 2008; Ve´gran et al., 2011), we next measured the effect of
MCT1 inhibition on lactate uptake in glycolytic breast cancer
cells. To assess lactate uptake, 11 mM 1-13C-lactate was added
to the normal culture medium of SUM149PT cells along with
250 nMAZD3965 or DMSO, and 24 hr later, metabolites were ex-
tracted from the cells and media and analyzed by liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS). AZD3965
treatment of SUM149PT cells had no effect on intracellular
lactate levels, extracellular lactate levels, or percentage of
13C-labeled intracellular lactate (Figures 3F and S3H–S3J). The
same experiment was conducted on SUM149PT cells cultured
in media lacking glutamine, and while the percentage of
13C-labeled intracellular lactate increased in the glutamine-
deprived cells, MCT1 inhibition again had no effect on lactate
levels or labeling (Figures 3F and S3H–S3J). These results sug-
gest that MCT1 does not impact lactate uptake in glycolytic
breast cancer cells.
Given that the published Km values for MCT1 interaction with
pyruvate are lower than those for other monocarboxylates
including lactate and acetate (Km pyruvate = 0.6–1.0 mM versus
Km lactate = 2.2–4.5 mM, Km acetate = 3.7) (Halestrap and Wil-
son, 2012), we next measured the effect of MCT1 inhibition on
pyruvate export rates. As shown in Figure 3D, all cell lines tested
show decreased pyruvate export rates upon MCT1 inhibition
with AZD3965, as well as upon stable MCT1 knockdown (Fig-
ure S3K). Reduced pyruvate export rates were also observednd Poor Breast and Lung Cancer Patient Survival
inoma (IDC) with an antibody toward MCT1 indicates higher MCT1 expression
istry on a breast tissue microarray is compared across breast histologies and
in situ (DCIS) (p = 0.003), invasive ductal carcinoma (IDC) (p < 0.001), and lymph
t glandular epithelium (‘‘normal’’) or epithelium from voluntary breast reductions
lium and ductal hyperplasia (Ductal Hyper.) lesions. Error bars denote SEM.
istry on a lung tissue microarray is compared across lung histologies and his-
eno ) (p < 0.001), adeno-squamous (Adeno-Squam) (p < 0.001), squamous cell
hial epithelium. Expression of MCT1 is significantly elevated in squamous and
(p < 0.001 for both). Error bars denote SEM. n, number of tissue array spots
ductal carcinoma of the breast. Kaplan-Meier survival plot shows patients with
nd higher MCT1 expression (R2.0 mean integrated intensity) depicted as a red
CLC. Kaplan-Meier survival plot shows patients with lower MCT1 expression
ression (>1.0 mean integrated intensity) depicted as a red line. n, number of
ge IV lung cancer patients. n, number of individuals in each category.
ors
(legend on next page)
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using an alternative shRNA sequence that knocks down MCT1
expression (Figures S3B, S3L, and S3M), and expression of
shRNA-resistant MCT1 cDNA rescued the reduced pyruvate
export rate caused by MCT1 knockdown (Figures S2N and
S2O). Consistent with a reduction in pyruvate export, MCT1 inhi-
bition with AZD3965 leads to an increase in intracellular pyruvate
levels (Figures 3G and S3P). Together these data confirm that
MCT1 loss of function reduces cellular pyruvate export.
To better understand the role of MCT1 in regulating lactate
versus pyruvate transport in breast cancer cells, we also
measured lactate and pyruvate export rates over a time course
post AZD3965-mediated MCT1 inhibition by analyzing metabo-
lites extracted from the media via gas chromatography-mass
spectrometry (GC-MS). We found that pyruvate media levels
are reduced by acute MCT1 inhibition in SUM149PT cells,
whereas lactate media levels are unchanged (Figure 3H). Other
breast cancer cell lines showed similar results (data not shown).
These data suggest that a primary function of MCT1 in glycolytic
breast cancer cells may be to mediate pyruvate export.
MCT1 Loss-of-Function Decreases Breast Cancer Cell
Proliferation In Vitro and Tumor Growth In Vivo
To examine whether MCT1 function affects breast cancer cell
proliferation and survival, we measured the proliferation rates
and viability of breast cancer cell lines stably expressing MCT1
shRNA or treated with AZD3965. MCT1 knockdown reduces
glycolytic breast cancer cell proliferation (Figure 4A), and this
proliferative defect is rescued by expression of shRNA-resistant
MCT1 cDNA (Figures 4A, 4B, S3B, and S3N). AZD3965 treat-
ment also reduces proliferation rates of glycolytic breast cancer
cell lines (Figure 4A), and dose-response curves for AZD3965
indicate that the reduction in proliferation in glycolytic breast
cancer cells tracks with the reduction in pyruvate export rate
caused by MCT1 inhibition (Figures S4C and S4D). Since
MCT1 inhibition leads to increased intracellular pyruvate levels
(Figure 3G), we wondered whether increased intracellular pyru-
vate levels could reduce proliferation of glycolytic breast cancer
cells. Consistent with this notion, treatment with 5 mM methyl-
pyruvate results in elevated intracellular pyruvate levels and
significantly reduced proliferation in glycolytic breast cancerFigure 3. MCT1 Is Critical for Pyruvate Export in Breast Cancer Cell Li
(A) Gene expression profiles fromSUM149PT cells expressing scrambled shRNA (
list of transcripts that are differentially expressed upon MCT1 knockdown. This r
FDG uptake in breast tumors from patients using the rank-rank hypergeometric
sented as a hypergeometric heat map, indicates that MCT1 knockdown renders
uptake. The direction-signed log10-transformed hypergeometric p values are ind
(B) Heatmap indicating fold changes in expression levels of genes in the oxida
AZD3965 (MCT1i) for 24 hr.
(C) Cellular oxygen consumption rates 24 hr post treatment with DMSO versus 2
(D) Lactate and pyruvate export rates 4 hr post treatment of the indicated cell lin
(E) Percentage of the 13C-labeledM1 lactate isotopomer from cells 24 hr post label
the presence or absence of 4 mM glutamine as determined by LC-MS/MS. Error
(F) Percentage of the 13C-labeled M2 lactate isotopomer from cells 24 hr post l
(MCT1i) as determined by LC-MS/MS. Error bars denote SD (n = 3).
(G) Intracellular pyruvate levels from the indicated cell lines treated with DMSO, 25
(H) Relative abundance of media lactate and pyruvate post treatment of SUM149P
GC-MS. *p < 0.05; **p < 0.01.
See also Figures S2 and S3.
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of cells in theG0/G1 phase of the cell cycle (Figure 4C). However,
apoptosis-mediated cell death as measured by annexin A5
staining is not affected byMCT1 knockdown in the breast cancer
cell lines tested (Figures S4E and S4F). These results suggest
that increased intracellular pyruvate levels as a result of MCT1
loss-of-function reduces proliferation of glycolytic breast cancer
cells without enhancing apoptosis.
The consistent reduction in proliferation rate upon MCT1
knockdown and AZD3965 treatment is surprising given that
these cells express other MCTs (Figure S4G), and MCT4 expres-
sion has been associated with resistance to MCT1 inhibition
(Doherty et al., 2014; Le Floch et al., 2011; Polanski et al.,
2014). MCT4 is expressed in the breast cancer cell lines tested
with relatively high expression in SUM149PT and SUM159PT
cells (Figure S4H). The MCT1 shRNA sequences used in this
study are not cognate to MCT2-4 mRNAs, and in fact
SUM149PT cells with stable expression of MCT1 shRNA exhibit
increased MCT2-4 transcript levels (Figure S2B). However,
MCT4 protein levels are not grossly altered in the context of
MCT1 knockdown or inhibition in the breast cancer cell lines
tested (Figure S4I). Additionally, protein levels of the MCT chap-
erone protein CD147 are not altered in the context of MCT1
knockdown or inhibition in the breast cancer cell lines tested
(Figure S4). Since we found that MCT1 loss-of-function reduces
proliferation of glycolytic breast cancer cells that express other
MCTs, including MCT4, our results suggest an important and
specific role for MCT1 function in breast cancer cell proliferation.
To examine whether MCT1 inhibition impacts tumor growth
and glycolysis in vivo, we generated mammary fat pad xenograft
tumors from SUM149PT cells in NOD scid gamma (NSG) mice
and began AZD3965 treatment after the tumors reached 5 mm
in diameter. AZD3965 treatment robustly blocked growth of
the mammary fat pad xenograft tumors, with significant differ-
ences in tumor growth between the vehicle-treated and
AZD3965-treated cohorts after only 1 week of treatment (Fig-
ure 4D). However, despite the reduced tumor growth, tumor
FDG uptake as measured by positron emission tomography
(PET) was not decreased in the AZD3965-treated mice and
insteadwas slightly but significantly increased (Figure 4E). Thesenes
control) and shRNA towardMCT1 (knockdown) were used to generate a ranked
anked list was compared to a ranked list of transcripts that correlate with high
overlap (RRHO) algorithm. The resulting overlap from the ranked lists, repre-
glycolytic SUM149PT breast cancer cells less similar to tumors with high FDG
icated in the accompanying color scale.
tive phosphorylation gene set from SUM149PT cells treated with DMSO or
50 nM AZD3965 (MCT1i). Error bars denote SEM (n = 5).
es with DMSO or 250 nM AZD3965 (MCT1i). Error bars denote SD (n = 3).
ingwith 1-13C-lactate and treatment with DMSOor 250 nMAZD3965 (MCT1i) in
bars denote SD (n = 3).
abeling with 1,2-13C-glucose and treatment with DMSO or 250 nM AZD3965
0 nMMCT1i, or 5 mMmethyl-pyruvate for 30 min. Error bars denote SD (n = 3).
T cells with 250 nM AZD3965 (MCT1i) for the indicated times as determined by
ors
(legend on next page)
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data are consistent with our in vitro results showing that
AZD3965 treatment reduces proliferation but not glycolytic flux
of breast cancer cells.
Given that we found that breast cancer cells adapt toMCT1 in-
hibition by enhancing oxidative metabolism (Figure 3C), we
reasoned that co-treatment of AZD3965 along with an oxidative
phosphorylation inhibitor may further reduce proliferation rates
of glycolytic breast cancer cells treated with AZD3965 by block-
ing the compensatory switch to increased oxidative metabolism.
We therefore tested the effects of the biguanides, metformin,
and phenformin, known inhibitors of mitochondrial complex I,
on glycolytic breast cancer cell proliferation in combination
with AZD3965 treatment. Consistent with our hypothesis, dual
treatment of AZD3965 with metformin or phenformin further low-
ered proliferation rates, beyond those seen with AZD3965 treat-
ment alone, in an additive to synergistic fashion inmultiple breast
cancer cell lines (Figure 4F). Similar synergistic effects between
MCT1 inhibition andmetformin treatment were recently reported
in mouse xenograft models of cancer (Doherty et al., 2014).
Collectively, these additive to synergistic effects of metformin
or phenformin dual treatment with AZD3965 in cancer cell lines
and tumors suggest a promising combination treatment strategy
for patients with glycolytic tumors.
DISCUSSION
Here, we show that MCT1 is critical for pyruvate export and pro-
liferation of glycolytic breast cancer cells (schematic representa-
tion in Figure 4G). MCT1 loss of function consistently reduces
pyruvate export, increases oxygen consumption, and reduces
proliferation rates. Dual treatment of AZD3965 with metformin
or phenformin further reduces proliferation rates, presumably
by blocking the compensatory switch to oxidative metabolism
caused by MCT1 inhibition to sustain proliferation. Our results
imply an important role for pyruvate export in promoting prolifer-
ation and reducing oxidative metabolism in glycolytic breast
cancer cell lines. However, the mechanism by which blocking
pyruvate export may impact proliferation remains unclear—
modulation of cellular redox status, intracellular pH, and/or
ATP levels could be involved. Additionally, the mechanism by
which MCT1 inhibition leads to increased cellular respiration re-
quires further investigation. Pyruvate export inhibition may lead
to increased entry of pyruvate carbons into the mitochondria toFigure 4. MCT1 Loss-of-Function Reduces Breast Cancer Cell Prolifer
(A) Proliferation rates of the indicated breast cancer cell lines stably expressing
scrambled shRNA (scramble shRNA), and vehicle (DMSO)-treated cells versus 2
(B) Proliferation rates of the indicated cell lines treated for 4 days with DMSO or
(C) Percentage of MCT1 knockdown cells (MCT1 shRNA) versus control cells (scra
*p < 0.05, **p < 0.01.
(D and E) Relative tumor volumes (D) and FDG-PET/CT images (E) from NSGmice
by oral gavage twice daily with either 0.5% hydroxypropyl methyl cellulose/0.1% t
and values shown represent mean injected dose per gram (%ID/g) calculated fro
(F) Proliferation rates of indicated breast cancer cell lines after 5 days of treatment
or phenformin (IC50), phenformin + MCT1i (IC50 for both). MCT1i was replenished
(G) Schematic representation of the impact ofMCT1 inhibition on breast cancer ce
increases oxygen consumption, and reduces proliferation rates. Dual treatment
presumably by blocking the compensatory switch to oxidative metabolism caus
See also Figure S4.
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our preliminary studies tracing the fate of 13C-glucose metabo-
lites, and specifically pyruvate, in MCT1-inhibited cells have
yielded varying results across the breast cancer cell lines tested.
Also, elevated oxygen consumption rates are observed at 24 hr
post AZD3965 treatment, but not at 30min or 4 hr post treatment
(Figure 3C), suggesting that the effect on respiration is not direct
but rather through programmed changes in transcription.
Consistent with this notion, genes involved in oxidative phos-
phorylation are enriched in breast cancer cells after 24 hr
AZD3965 treatment (Figures 3B and S2F). These changes in
gene expression may occur through an unknown mechanism
downstream of MCT1 inhibition and reduction of pyruvate
export, or may simply be a cellular adaptation to survive MCT1
inhibition. It will be interesting to determine whether similar
changes in gene expression also happen in tumors of breast
cancer patients treated with AZD3965.
Doherty et al. (2014) recently found that MCT1 inhibition
blocks lactate transport and decreases glycolysis to ultimately
trigger cancer cell death in lymphoma and breast cancer cells,
however, we did not observe reduced lactate export, decreased
glycolysis, or increased cell death uponMCT1 inhibition in glyco-
lytic breast cancer cell lines. One potential explanation for these
discrepancies is the varying levels of MCT4 in the different cell
lines used. The Burkitt lymphoma cell lines and MCF7 and
T47D breast cancer cell lines used in the study by Doherty
et al. (2014) expressed very little, if any, MCT4. In contrast, the
relatively more glycolytic breast cancer cell lines used in our
study—SUM149PT, SUM159PT, and HS578T (Figure S1B)—ex-
pressed measurable amounts of MCT4 (Figures S4G and S4H).
MCT4 expression is likely responsible for continued lactate
transport that likely sustains the glycolytic flux and survival of
glycolytic breast cancer cell lines in the context of MCT1 inhibi-
tion. Consistent with an important role for lactate export in pro-
moting cancer cell proliferation, and in agreement with results
shown by Doherty et al. (2014), we found that supplementation
of complete medium with 11 mM lactate reduced proliferation
of glycolytic breast cancer cells that co-express MCT1 and
MCT4 (data not shown).
Previous reports have found that MCT1 and MCT4 are
commonly co-expressed in tumors (Choi et al., 2014; Kim
et al., 2015). In support of this notion, we have found that
MCT1 and MCT4 are often coexpressed at the mRNA level ination and Tumor Growth
shRNA that knocks down MCT1 expression (MCT1 shRNA) versus control
50 nM AZD3965 (MCT1i). Error bars denote SD (n = 3). *p < 0.05, **p < 0.01.
5 mM methyl-pyruvate. Error bars denote SD (n = 3). *p < 0.05, **p < 0.01.
mble shRNA) in the G0/G1 phase of the cell cycle. Error bars denote SD (n = 3).
with mammary fat pad xenograft tumors derived from SUM149PT cells treated
ween (vehicle) or 0.1 ml/10 g AZD3965 (MCT1i) for 7 days. (E) T indicates tumor,
m tumor regions of interest. Error bars denote SEM.
with DMSO, MCT1i (IC50), metformin (IC50), metformin + MCT1i (IC50 for both),
every day. *p < 0.05, **p < 0.01.
ll metabolism and proliferation. AZD3965 consistently reduces pyruvate export,
of AZD3965 with metformin or phenformin further reduces proliferation rates,
ed by MCT1 inhibition to sustain proliferation.
ors
patient breast and lung tumors (Figures S4L and S4M). Examina-
tion of MCT1 and MCT4 mRNA levels across cancer cell lines
shows a high number of cancer cell lines with dual expression
of MCT1 andMCT4 and another population with high expression
of MCT1 only (Figure S4N). Although several previous studies
have found that MCT1 modulates cancer cell lactate transport
in the absence of MCT4 expression, our results support a
lactate-transport independent role for MCT1 in promoting prolif-
eration of cancer cells with naturally derived dual MCT1/MCT4
expression. One potential reason why cancer cells may upregu-
lateMCT1 expression even in the context of MCT4 expression, is
the ability of MCT1, but not MCT4, to transport both lactate and
pyruvate to ensure cytosolic redox equilibration between cells
and tissues (Halestrap and Wilson, 2012). Future experiments
on patient-derived primary breast cancers that exclusively ex-
pressMCT1, MCT4, or both together, are needed tomore clearly
delineate the roles of MCT1 versus MCT4 in tumor metabolism
and growth.
AZD3965 is thought to kill tumor cells reliant on glycolysis
through inhibition of lactate transport (Doherty et al., 2014; Po-
lanski et al., 2014). However, our data suggest that AZD3965
does not reduce lactate export, glycolytic flux, or survival of
glycolytic breast cancer cell lines coexpressing MCT1 and
MCT4 in vitro, but still impacts proliferation through an alterna-
tive mechanism, potentially via reduction of pyruvate export
and/or induction of oxidative metabolism. In our mammary fat
pad xenograft model, AZD3965 treatment blocked tumor growth
despite causing a slight increase in tumor FDG uptake as
measured by PET. These data support an alternativemode of ac-
tion for AZD3965 than impaired glycolysis in blocking tumor
growth and suggest that loss of tumor FDG uptake by PET is
not a good biomarker of response to AZD3965 in breast cancer
patients.
Pyruvate is a commonly secreted metabolite from cancer cell
lines in vitro (Jain et al., 2012), however, whether pyruvate is
secreted from tumors in vivo remains unknown. Our finding
that serum samples from stage IV lung cancer patients have
elevated pyruvate levels compared to serum from stage I lung
cancer patients is consistent with MCT1 modulation of tumor
pyruvate export in vivo (Figure 2E). However, further studies
are necessary to confirm MCT1-mediated pyruvate export
from cancer cells within tumor tissues and to determine whether
and how pyruvate export impacts tumor growth. Our results
expand upon a growing literature that MCT1 is necessary for
optimal cancer cell proliferation and provide further support for
use of MCT1 inhibitors as anti-cancer therapeutics.EXPERIMENTAL PROCEDURES
Cell Culture Conditions
HS578T cells were grown in DMEM media with 1% Penstrep and 10% FBS.
SUM149PT and SUM159PT cells were grown in F12 media with 1% Penstrep,
10% FBS, 10 mg/ml insulin, 10 mg/ml hydrocortisone, 10 ng/ml EGF, and
0.5 mg/ml of gentamicin.
Enrichment Analysis
Gene expression data were analyzed using gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) and rank-rank hypergeometric overlap
(RRHO) (Plaisier et al., 2010) algorithms as described previously (PalaskasCell Ret al., 2011). Pathway annotations for GSEA were from (1) KEGG metabolic
pathways (Kanehisa et al., 2010), or (2) the MSigDB curated gene sets (Subra-
manian et al., 2005). To visualize gene expression data within the context of
metabolic pathway structure, we used Cytoscape (Smoot et al., 2011) to color
code the KEGG glycolysis pathway genes (hsa00010) on a green-to-red scale
according to the average Pearson correlation with glycolytic phenotype. The
accession number for the microarray data reported in this paper is [GEO]:
[GSE76675].
Immunohistochemistry
Paraffin-embedded breast and lung cancer tissue microarray blocks were cut
into 4-mm sections immediately prior to immunohistochemistry with polyclonal
MCT1 antibody, and staining, blinded scoring, and statistical analyses were
carried out as described previously (Mah et al., 2007, 2011; Yoon et al.,
2010a, 2010b). Comparisons of MCT1 expression across lung and breast his-
topathological categories were performed using Kruskal-Wallis tests, and the
Cox proportional hazards model was used to determine prognostic values of
survival.
Measurement of Glucose Consumption Rates and Pyruvate/Lactate
Export Rates
Glucose consumption and lactate export rates were measured using a NOVA
Bioanalyzer, and oxygen consumption rates were measured using a Seahorse
XF-3 analyzer. Serumpyruvate/lactate levels and pyruvate/lactate export rates
were measured using an absorbance-based assay kit (BioVision) and GC-MS.
Following MCT1 inhibition accomplished by treating cells with 250 nM
AZD3965, pyruvate/lactate export rates were measured using colorimetric-
based assay kits (BioVision).
Intracellular Metabolite Analysis Using LC-MS
Cells were carefully scraped off in 800 ml of 50% ice cold methanol. An internal
standard of 10 nmol norvaline was added to the cell suspension, followed by
400 ml of cold chloroform. After vortexing for 15 min, the aqueous layer was
transferred to a glass vial and the metabolites dried under vacuum. Metabo-
lites were resuspended in 100 ml 70%acetonitrile (ACN) and 5 ml of this solution
used for the mass spectrometer-based analysis. The analysis was performed
on a Q Exactive (Thermo Scientific) in polarity-switching mode with positive
voltage 3.0 kV and negative voltage 2.25 kV. The mass spectrometer was
coupled to an UltiMate 3000RSLC (Thermo Scientific) UHPLC system. Mobile
phase A was 5 mM NH4AcO [pH 9.9], mobile phase B was ACN, and the sep-
aration was achieved on a Luna 3 mm NH2 100A column (150 3 2.0 mm)
(Phenomenex).
The flow was 300 ml/min, and the gradient ran from 15% A to 95% A in
18 min, followed by an isocratic step for 9 min and re-equilibration for 7 min.
Metabolites were detected and quantified as area under the curve (AUC)
based on retention time and accurate mass (%3 ppm) using the TraceFinder
3.1 (Thermo Scientific) software. Relative amounts of metabolites between
various conditions, as well as percentage of labeling was calculated, corrected
for naturally occurring 13C abundance as described (Yuan et al., 2008) and de-
picted in bar graphs.
Cell Culture Medium Metabolite Analysis Using GC-MS
A total of 2.5 3 105 cells of each breast cancer cell line were seeded onto
6-well plates, medium was replaced after 24 hr, and inhibitor added at appro-
priate times. Twenty microliters of cell-free medium samples were taken 24 hr
thereafter. Metabolites were extracted by adding 300 ml 80% methanol to the
medium samples, followed by vortexing three times, then centrifugation for
10 min at 13,000 rpm at 4C. The supernatant was transferred to a fresh
tube, and the solvent was evaporated using a SpeedVac.Metabolites were de-
rivatized by adding 20 ml of 2% methoxyamine hydrochloride in pyridine
(Pierce) for 1.5 hr at 37C followed by 30 ml N-methyl-N-(tert-butyldimethyl-
silyl)trifluoroacetamide (Pierce) for 1 hr at 55C. Samples were run on an
Agilent 5975C MSD coupled to an Agilent 7890A GC as described (Metallo
et al., 2012). Data extraction was done with Agilent MSD ChemStation soft-
ware and analysis performed with Microsoft Excel. Metabolite isotopomers
were not corrected for naturally occurring 13C.eports 14, 1590–1601, February 23, 2016 ª2016 The Authors 1599
Xenograft Models and MicroPET/CT Imaging
Breast cancer tumor xenografts were generated by injecting 1 3 106
SUM149PT cells into female NSG mice. Half of the mice were treated with
MCT1i (AZD3965) once tumors reached a size of 5 mm in diameter and were
treated twice daily by oral gavage. Half of the mice were treated as control
mice with an equal volume of vehicle. Tumor size was monitored every other
day with calipers. For microPET imaging, animals were anesthetized with
1.5% isoflurane, USP (Phoenix Pharmaceutical) and injected intravenously
with 200 uCi 18F-FDG. PET imaging was conducted on a Focus 220 microPET
scanner (Siemens) and, subsequently, computed tomography (CT) recorded
using a MicroCAT II CT instrument (Siemens). Data were analyzed by drawing
three-dimensional region of interests (ROIs) using AMIDE software (Loening
and Gambhir, 2003).
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE76675.
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